- Home
- DXYZ vs ALLO Comparison
DXYZ vs ALLO Comparison
Compare DXYZ & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXYZ | ALLO |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 563.5M | 539.4M |
| IPO Year | 2024 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DXYZ | ALLO |
|---|---|---|
| Price | $29.78 | $3.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $8.73 |
| AVG Volume (30 Days) | 2.3M | ★ 7.6M |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $144,130.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.71 | $0.86 |
| 52 Week High | $50.50 | $4.46 |
Technical Indicators
Market Signals| Indicator | DXYZ | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 57.71 | 66.63 |
| Support Level | $25.10 | $1.10 |
| Resistance Level | $33.28 | N/A |
| Average True Range (ATR) | 2.22 | 0.30 |
| MACD | 0.24 | 0.06 |
| Stochastic Oscillator | 54.98 | 43.83 |
Price Performance
Historical ComparisonAbout DXYZ Destiny Tech100 Inc.
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It is designed to be an investment portfolio of the Top 100 High-Growth Tech Companies.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.